Avzivi® (BAT1706) is Bio-Thera Solution’second FDA approved product in the United States Avzivi® is the second biosesimilar researched,developed, and manufactured by a Chinese pharmaceutical company to receive FDAapproval in the United States Guangzhou, China – December 7, 2023 – Bio-TheraSolu...
DetailsGUANGZHOU, China --- Bio-Thera Solutions (688177:SH), acommercial-stage biopharmaceutical company developing a pipeline of innovativetherapies and biosesimilars, today announced the company has reached a licensing agreement with Mega Lifesciences PCL for BAT 17 06, its bevacizumab biosesimilar, under wh...
GUANGZHOU, China ---(Businesswire)--- Bio-TheraSolutions, Ltd (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and a pipeline of biosesimilars,today announced the company has entered into a licensing and supply agreement with BiommSA, for BAT 22 06...
GUANGZHOU, CHINA, April 14, 2023 – Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, todayannounced the company will present one poster concerning Phase 1 clinicalresults for BAT1006 at the 2023 American Association for Cancer Research("AACR") Annual Meeting taking ...
